Skip to main content
. 2021 Jan 1;25(1):87–94. doi: 10.4196/kjpp.2021.25.1.87

Fig. 1. Inhibitory effects of nootkatol on the human TRPV1 (hTRPV1) and human ORAI1 (hORAI1) currents.

Fig. 1

(A) Representative chart trace recording of hTRPV1 inhibited by nootkatol in hTRPV1-overexpressing HEK293T cells. The solid line indicates the holding current, whereas solid bars indicate the corresponding current induced by ramp-like pulse. After hTRPV1 activation by 1 µM capsaicin, the marked states indicate the steady-state currents of each condition, namely control (1) and treatment with 10 (2), 30 (3), and 90 µM (4) nootkatol. (B) Related current-voltage (I–V) relationship curve at the steady-state of the control (1) and cells treated with 10 (2), 30 (3), and 90 µM (4) nootkatol. (C) Summary of current inhibition by nootkatol treatment. Current amplitude is normalized to control current at –60 mV (mean ± standard error of the mean [SEM], n = 7, 4, 4, 7, respectively) (***p < 0.001). (D) Representative chart trace recording of hORAI1 inhibited by nootkatol in hORAI1-overexpressing HEK293T cells. (E) Related current-voltage (I–V) relationship curve at the steady-state of the control (1) and cells treated with 10 (2), 30 (3), and 90 µM (4) nootkatol. (F) Summary of the current level of hORAI1 upon nootkatol treatment. Current amplitude is normalized to control current at –120 mV (mean ± SEM, n = 7, 6, 6, 4, respectively) (***p < 0.001).